Gonadotropin-releasing hormone analogue therapy for peritoneal inclusion cysts after gynecological surgery

S. Nozawa, Takashi Iwata, H. Yamashita, Kouji Banno, K. Kubushiro, R. Aoki, K. Tsukazaki

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: The purpose of this report is to estimate the effectiveness of gonadotropin-releasing hormone analogue (Gn-RHa) therapy for peritoneal inclusion cysts. Methods: Patients who had cystic masses that developed after gynecological surgery and were strongly suspected of being peritoneal inclusion cysts based on the results of ultrasound, magnetic resonance imaging (MRI), and tumor marker studies, were treated with a Gn-RHa (buserelin acetate or leuprorelin acetate). Buserelin acetate was administered at a dose of 900 μg/day, and leuprorelin acetate at a dose of 3.75 mg/month. Ultrasonography was performed in the outpatient clinic every 2 weeks after the start of administration to measure the diameter of cysts. Results: We treated 8 patients with peritoneal inclusion cysts conservatively with a Gn-RHa. The cysts resolved in 7 of the patients. Two of them developed a recurrence, but further Gn-RHa therapy was followed by complete resolution of the cysts in one patient and we resume Gn-RHa therapy to the other patient. The peritoneal inclusion cysts failed to shrink in only one patient. Conclusion: It is suggested that Gn-RHa therapy is effective in some cases of peritoneal inclusion cysts.

Original languageEnglish
Pages (from-to)389-393
Number of pages5
JournalJournal of Obstetrics and Gynaecology Research
Volume26
Issue number6
Publication statusPublished - 2000

Fingerprint

Gynecologic Surgical Procedures
Gonadotropin-Releasing Hormone
Cysts
Buserelin
Leuprolide
Therapeutics
Acetates
Tumor Biomarkers
Ambulatory Care Facilities
Ultrasonography
Magnetic Resonance Imaging
Recurrence

Keywords

  • Conservative therapy
  • Gonadotropin-releasing hormone analogue
  • Peritoneal inclusion cysts

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Gonadotropin-releasing hormone analogue therapy for peritoneal inclusion cysts after gynecological surgery. / Nozawa, S.; Iwata, Takashi; Yamashita, H.; Banno, Kouji; Kubushiro, K.; Aoki, R.; Tsukazaki, K.

In: Journal of Obstetrics and Gynaecology Research, Vol. 26, No. 6, 2000, p. 389-393.

Research output: Contribution to journalArticle

@article{963006aaeb9340ef88fa535550c88cd8,
title = "Gonadotropin-releasing hormone analogue therapy for peritoneal inclusion cysts after gynecological surgery",
abstract = "Objective: The purpose of this report is to estimate the effectiveness of gonadotropin-releasing hormone analogue (Gn-RHa) therapy for peritoneal inclusion cysts. Methods: Patients who had cystic masses that developed after gynecological surgery and were strongly suspected of being peritoneal inclusion cysts based on the results of ultrasound, magnetic resonance imaging (MRI), and tumor marker studies, were treated with a Gn-RHa (buserelin acetate or leuprorelin acetate). Buserelin acetate was administered at a dose of 900 μg/day, and leuprorelin acetate at a dose of 3.75 mg/month. Ultrasonography was performed in the outpatient clinic every 2 weeks after the start of administration to measure the diameter of cysts. Results: We treated 8 patients with peritoneal inclusion cysts conservatively with a Gn-RHa. The cysts resolved in 7 of the patients. Two of them developed a recurrence, but further Gn-RHa therapy was followed by complete resolution of the cysts in one patient and we resume Gn-RHa therapy to the other patient. The peritoneal inclusion cysts failed to shrink in only one patient. Conclusion: It is suggested that Gn-RHa therapy is effective in some cases of peritoneal inclusion cysts.",
keywords = "Conservative therapy, Gonadotropin-releasing hormone analogue, Peritoneal inclusion cysts",
author = "S. Nozawa and Takashi Iwata and H. Yamashita and Kouji Banno and K. Kubushiro and R. Aoki and K. Tsukazaki",
year = "2000",
language = "English",
volume = "26",
pages = "389--393",
journal = "Asia-Oceania Journal of Obstetrics and Gynaecology",
issn = "1341-8076",
publisher = "Blackwell Publishing Asia",
number = "6",

}

TY - JOUR

T1 - Gonadotropin-releasing hormone analogue therapy for peritoneal inclusion cysts after gynecological surgery

AU - Nozawa, S.

AU - Iwata, Takashi

AU - Yamashita, H.

AU - Banno, Kouji

AU - Kubushiro, K.

AU - Aoki, R.

AU - Tsukazaki, K.

PY - 2000

Y1 - 2000

N2 - Objective: The purpose of this report is to estimate the effectiveness of gonadotropin-releasing hormone analogue (Gn-RHa) therapy for peritoneal inclusion cysts. Methods: Patients who had cystic masses that developed after gynecological surgery and were strongly suspected of being peritoneal inclusion cysts based on the results of ultrasound, magnetic resonance imaging (MRI), and tumor marker studies, were treated with a Gn-RHa (buserelin acetate or leuprorelin acetate). Buserelin acetate was administered at a dose of 900 μg/day, and leuprorelin acetate at a dose of 3.75 mg/month. Ultrasonography was performed in the outpatient clinic every 2 weeks after the start of administration to measure the diameter of cysts. Results: We treated 8 patients with peritoneal inclusion cysts conservatively with a Gn-RHa. The cysts resolved in 7 of the patients. Two of them developed a recurrence, but further Gn-RHa therapy was followed by complete resolution of the cysts in one patient and we resume Gn-RHa therapy to the other patient. The peritoneal inclusion cysts failed to shrink in only one patient. Conclusion: It is suggested that Gn-RHa therapy is effective in some cases of peritoneal inclusion cysts.

AB - Objective: The purpose of this report is to estimate the effectiveness of gonadotropin-releasing hormone analogue (Gn-RHa) therapy for peritoneal inclusion cysts. Methods: Patients who had cystic masses that developed after gynecological surgery and were strongly suspected of being peritoneal inclusion cysts based on the results of ultrasound, magnetic resonance imaging (MRI), and tumor marker studies, were treated with a Gn-RHa (buserelin acetate or leuprorelin acetate). Buserelin acetate was administered at a dose of 900 μg/day, and leuprorelin acetate at a dose of 3.75 mg/month. Ultrasonography was performed in the outpatient clinic every 2 weeks after the start of administration to measure the diameter of cysts. Results: We treated 8 patients with peritoneal inclusion cysts conservatively with a Gn-RHa. The cysts resolved in 7 of the patients. Two of them developed a recurrence, but further Gn-RHa therapy was followed by complete resolution of the cysts in one patient and we resume Gn-RHa therapy to the other patient. The peritoneal inclusion cysts failed to shrink in only one patient. Conclusion: It is suggested that Gn-RHa therapy is effective in some cases of peritoneal inclusion cysts.

KW - Conservative therapy

KW - Gonadotropin-releasing hormone analogue

KW - Peritoneal inclusion cysts

UR - http://www.scopus.com/inward/record.url?scp=0034524195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034524195&partnerID=8YFLogxK

M3 - Article

C2 - 11152322

AN - SCOPUS:0034524195

VL - 26

SP - 389

EP - 393

JO - Asia-Oceania Journal of Obstetrics and Gynaecology

JF - Asia-Oceania Journal of Obstetrics and Gynaecology

SN - 1341-8076

IS - 6

ER -